Skip to main content

Advertisement

Table 4 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with Herceptin® and Paclitaxel in gastric cancer cell lines

From: Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines

YBC-2 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX     1.24 0.98 0.9
HER     1201.02 0.32 0.92
TAX + HER 6.03 14.77 36.21 0.85 0.54 0.82
Diagnosis combined effect antagonism antagonism antagonism    
YBC-3 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX     9.609 2.129 0.940
HER     46.063 0.623 0.970
TAX + HER 0.225 0.172 0.185 7.010 1.220 0.889
Diagnosis combined effect synergy synergy synergy    
NCI-N87 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX     1.49 1.56 0.96
HER     113350 0.19 0.63
TAX + HER 1747.94 0.81 0 858.42 −0.16 0.90
Diagnosis combined effect antagonism synergy synergy    
U-87 MG Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX     0.79 0.89 0.87
HER     1845.53 0.46 0.86
TAX + HER 361.02 1571.47 6840.35 1.27 0.41 0.89
Diagnosis combined effect antagonism antagonism antagonism    
SK-BR-3 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX     0.42 1.11 0.96
HER     1.42E + 06 0.05 0.43
TAX + HER 0.05 0.24 1.12 0 0.44 0.88
Diagnosis combined effect synergy synergy antagonism    
  1. TAX, Paclitaxel; HER, Herceptin.